Akt/PKB signaling plays a central role in many biological functions, such as cell proliferation, apoptosis, cell metabolism, and protein translation. Although it is well known that Akt activation is regulated by phosphorylation, it is unclear whether other types of the posttranslational modifications, such as ubiquitination, are also involved in Akt activation. In this proposal, we have identified TRAF6 as a potential Akt E3 ligase that induces Akt K63-linked polyubiquitination and is critical for Akt phosphorylation and activation. Our results reveal that Akt K63 polyubiquitination may represent a novel mechanism by which oncogenic Akt signaling is regulated and that this study may have important clinical implications for the treatment of cancer. The objective of this application, which is the next step in pursuit of that goal, is to determine the potential role of TRAF6 and Akt K63-linked polyubiquitination in cancer progression and metastasis. The central hypothesis of the application is that Akt K63-linked polyubiquitination induced by TRAF6 orchestrates Akt membrane localization and subsequent phosphorylation. Our central hypothesis has been formulated on the basis of our strong preliminary data. The rationale of the proposed research is that, once the important role of TRAF6 and Akt polyubiquitination is confirmed and established in cancer progression and metastasis, the better treatment or target for human cancers can be achieved. We plan to test our central hypothesis and accomplish the objective of this application by pursuing the following specific aims:
Aim 1) To determine the molecular mechanism by which Akt polyubiquitination regulates Akt activation.
Aim 2) To determine the molecular mechanism by which Akt ubiquitination and deubiquitination are regulated.
Aim 3) To determine in vivo role of TRAF6 in tumorigenesis and metastasis. This proposal work is innovative, because it provides for the first time that TRAF6 is an E3 ligase for Akt and Akt K63-linked polyubiquitination orchestrate Akt phosphorylation and activation. With respected outcomes, the combination of work in this proposal is collectively expected to uncover the critical role of TRAF6 and Akt K63-linked polyubiquitination in cancer development and metastasis. Such results will have an important positive impact, because identification of the important role of TRAF6 and Akt K63-linked polyubiquitination in cancer progression and metastasis may therefore provide potentially therapeutic targets for cancer treatment. Our results will also fundamentally advance our current understandings of how oncogenic Akt signaling is regulated and may have important clinical implications.

Public Health Relevance

Although the extensive studies have been made for the role of PI3K/Akt signaling in cancers, how Akt membrane localization and phosphorylation is regulated remains largely unknown. Our study reveals that a novel posttranslational modification is operated on Akt and that Akt K63-linked polyubiquitnation by E3 ligase TRAF6 may play important roles in Akt membrane localization, phosphorylation, and tumorigenesis. Understanding the mechanism by which Akt activation is regulated may not only provide a great insight into how the oncogenic Akt signaling is regulated, but also offer the important therapeutic implications for human cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA149321-05
Application #
8607156
Study Section
Cellular Signaling and Regulatory Systems Study Section (CSRS)
Program Officer
Jhappan, Chamelli
Project Start
2010-04-01
Project End
2015-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
5
Fiscal Year
2014
Total Cost
$286,214
Indirect Cost
$105,066
Name
University of Texas MD Anderson Cancer Center
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Feng, Haizhong; Lopez, Giselle Y; Kim, Chung Kwon et al. (2014) EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest 124:3741-56
Chan, Chia-Hsin; Morrow, John Kenneth; Li, Chien-Feng et al. (2013) Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154:556-68
Jin, Guoxiang; Wang, Ying-Jan; Lin, Hui-Kuan (2013) Emerging Cellular Functions of Cytoplasmic PML. Front Oncol 3:147
Yang, Wei-Lei; Jin, Guoxiang; Li, Chien-Feng et al. (2013) Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal 6:ra3
Wu, J; Lee, S-W; Zhang, X et al. (2013) Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex. Oncogene 32:78-85
Wu, Ching-Yuan; Kang, Hong-Yo; Yang, Wei-Lei et al. (2011) Critical role of monoubiquitination of histone H2AX protein in histone H2AX phosphorylation and DNA damage response. J Biol Chem 286:30806-15
Chan, Chia-Hsin; Gao, Yuan; Moten, Asad et al. (2011) Novel ARF/p53-independent senescence pathways in cancer repression. J Mol Med (Berl) 89:857-67
Yang, W-L; Zhang, X; Lin, H-K (2010) Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 29:4493-503
Yang, Wei-Lei; Wang, Jing; Chan, Chia-Hsin et al. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325:1134-8